Recruiting

NCT Number: NCT07435168

CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis

The objective of this observational, prospective study is to determine the prevalence of Cardiac Amyloidosis (CA) in males over the age of 65 who experience chest pain but show no signs of coronary artery disease (CAD).

Prior to inclusion, all patients will have undergone a CT coronary angiogram or an Rb-PET scan to rule out the possibility of CAD.

Participants will be subject to several examinations, including blood tests, urine samples, ECG, echocardiography, and bone scintigraphy. An endomyocardial biopsy may be conducted if necessary.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiac Amyloidosis Amyloid Neuropathies Amyloid Neuropathies, Familial Amyloidosis Amyloidosis, Familial Chest Pain Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Neurodegenerative Diseases Neurologic Manifestations Neuromuscular Diseases Nutritional and Metabolic Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Proteostasis Deficiencies Signs and Symptoms

Age range

65 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Rigshospitalet

Copenhagen, 2100, Denmark

Location status: Recruiting

Location contact

Emil Fosbøl, MD,

PRINCIPAL_INVESTIGATOR

Navid Noory, MD

CONTACT

[email protected]

+4535453108

Navid Noory, MD, Phd-fellow

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

No signs of CAD through Rb-PET and/or CT coronary arteriogram

Exclusion criteria

Previous history of amyloidosis

Treatment and study plan

Screening thourgh examinations including bonescintigraphy

Other

Clinical examination, blood samples, echo, bone scintigraphy

Primary outcomes

Prevalence of ATTR-CA in patients experiencing chest pain

Time frame: Up to 4 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Navid Noory, MD

CONTACT

[email protected]

4535453108

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Acronym: CHEST-CA

Important dates

Study start: 2024
Primary completion: 2027
Study completion: 2027
First posted: Feb 27, 2026
Registry last updated: Feb 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting